The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

The newly released data from the phase 3 STOP-HS program, which includes STOP-HS1 and STOP-HS2, show that povorcitinib is potentially safe and effective for the treatment of moderate to severe HS.

While both the late studies STOP-HS1 and STOP-HS2 studies met their primary endpoint, the results lagged investor expectations, and consequently, shares declined. Shares of Incyte have lost 7.2% ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Also Read: Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss STOP-HS1 and STOP-HS2 studies met their primary endpoint at both ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del., March 17, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive ...